Within this context, we previously identified an allo-HLA-restricted and tumor-specific Vγ5Vδ1TCR derived from clone FE11, introduced in the TEG concept as TEG011, which was, although not dependent on a defined peptide, selectively targeting HLA-A*24:02+ tumor cells without impairing the healthy tissues (34). This evidence concerns the gene HLA-A and neoplasm.